Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript
Operator: Good day and welcome to Arcutis Biotherapeutics' 2025 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Arcutis Biotherapeutics Inc. (ARQT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Royce & Associates Chuck Royce | 267,612 | $4,185,452 | 0.05% | |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 86,925 | $1,359,507 | -21% | 0.01% |
| 3. | ZWEIG DIMENNA PARTNERS Joe Dimenna | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.11 | 1,093 | Officer | 137,728 | 2024-11-30 | Filing | |
| $7.11 | 1,657 | Officer | 187,030 | 2024-11-30 | Filing | |
| $1.69 | 4,000 | Officer | 185,373 | 2024-05-31 | Filing | |
| $7.11 | 2,038 | Officer, Director | 838,430 | 2024-11-30 | Filing | |
| $1.69 | 4,000 | Officer, Director | 836,392 | 2024-05-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.59 | 3,871 | Officer | 115,468 | 2025-05-08 | Filing | |
| $15.20 | 5,030 | Officer | 204,399 | 2025-05-02 | Filing | |
| $15.19 | 11,448 | Officer, Director | 913,795 | 2025-05-02 | Filing | |
| $15.19 | 2,597 | Officer | 119,339 | 2025-05-02 | Filing | |
| $14.64 | 10,000 | Director | 111,944 | 2025-05-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,360,875 | $177,684,084 | 0.12% | |
| 2. | 8,892,337 | $139,076,152 | 0% | |
| 3. | 6,818,078 | $106,634,740 | 0% | |
| 4. | 1,103,413 | $17,257,380 | 0% | |
| 5. | 860,768 | $13,462,412 | 0% |
News See All
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2024 Earnings Call Transcript February 25, 2025Arcutis Biotherapeutics, Inc. beats earnings expectations.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Arcutis Biotherapeutics 2024 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Small Cap Stocks with High Potential
As we transition from a tumultuous summer in the financial markets, characterized by rising expectations for interest rate cuts and the consequent impacts on stock and bond performances, investors are...
10 Best Biotech Stocks To Buy Under $20
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological advancements, and government support.
10 Best Small-Cap Healthcare Stocks To Buy Now
In difficult economic times, healthcare equities are sometimes regarded as a defensive investment.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2024 Earnings Call Transcript
Operator: Hello, and thank you for standing by. Welcome to Arcutis Biotherapeutics Q2 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript
Operator: Good day and welcome to Arcutis Biotherapeutics' 2024 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.72 EPS, expectations were $-0.65. Arcutis Biotherapeutics, Inc.
5 High Growth Micro-cap Stocks to Buy
3 Wall Street analysts covered Blade Air Mobility, Inc. (NASDAQ:BLDE) over the last three months, and all kept a Buy rating on the stock.